Earnings
Voyager Therapeutics Corrects Earnings Classification — Its Reported Results Stay Unchanged
The correction leaves intact Voyager’s earlier cash outlook and plans for Alzheimer’s trial data.
Voyager Therapeutics (VYGR) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
The correction leaves intact Voyager’s earlier cash outlook and plans for Alzheimer’s trial data.
Earnings
The biotech expects Alzheimer’s imaging results in the fourth quarter and first gene-therapy dosing in the coming months, pending enrollment.
SEC Filings
The board's pick is expected to take over as CEO after initial safety data from an Alzheimer's gene therapy trial, with a $625,000 salary.